Show simple item record

Higher population‐based incidence rates of triple‐negative breast cancer among young African‐American women

dc.contributor.authorAmirikia, Kathryn C.en_US
dc.contributor.authorMills, Paulen_US
dc.contributor.authorBush, Jasonen_US
dc.contributor.authorNewman, Lisa A.en_US
dc.date.accessioned2011-11-10T15:40:07Z
dc.date.available2012-07-12T17:42:25Zen_US
dc.date.issued2011-06-15en_US
dc.identifier.citationAmirikia, Kathryn C.; Mills, Paul; Bush, Jason; Newman, Lisa A (2011). "Higher population‐based incidence rates of triple‐negative breast cancer among young African‐American women ." Cancer 117(12): 2747-2753. <http://hdl.handle.net/2027.42/87175>en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/87175
dc.description.abstractBACKGROUND: Differences in the breast cancer burden of African‐American women compared with white American women are well documented. Recent controversies have emerged regarding age‐appropriate mammographic screening guidelines, and these surveillance recommendations may influence future breast cancer disparities. The objective of the current study was to evaluate age‐specific breast cancer stage distributions and incidence rates of triple‐negative breast cancer (TNBC) in a population‐based tumor registry. METHODS: The authors analyzed breast cancers from the California Cancer Registry (CCR) that were diagnosed between 1988 and 2006. The results were stratified by age and race/ethnicity, with white Americans identified as non‐Hispanic whites (NHWs) and African Americans identified as non‐Hispanic blacks (NHBs). Breast cancer stage distributions and TNBC incidence rates also were analyzed. RESULTS: In total, 375,761 invasive breast cancers were evaluated (including 276,938 in NHWs and 21,681 in NHBs). NHBs and Hispanics tended to be younger than NHWs (median ages 57 years, 54 years, and 64 years, respectively). Lifetime incidence rates were higher for NHWs compared with NHBs and Hispanics; however, for women aged <44 years, incidence was highest among NHBs. NHBs also had higher incidence rates of stage III and IV disease and a higher incidence of TNBC in all age categories. CONCLUSIONS: Population‐based data demonstrated that African‐American women had a more advanced stage distribution for breast cancer compared with white American women and higher incidence rates for TNBC. These patterns were observed for women ages 40 to 49 years and for older women, and they suggest that mammographic screening for the early detection of breast cancer will be particularly relevant for younger African‐American women. Cancer 2011. © 2011 American Cancer Society. The California Cancer Registry revealed higher population‐based incidence rates of early onset, advanced‐stage, and triple‐negative breast cancer for African‐American women compared with white American women. These findings suggested that mammographic screening will be particularly important for young African‐American women.en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.titleHigher population‐based incidence rates of triple‐negative breast cancer among young African‐American womenen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumBreast Care Center, University of Michigan Cancer Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDepartment of Surgery, University of California San Francisco, Fresno, Californiaen_US
dc.contributor.affiliationotherDepartment of Medicine, University of California San Francisco, Fresno, Californiaen_US
dc.contributor.affiliationotherDepartment of Biology, California State University, Fresno, Californiaen_US
dc.contributor.affiliationother1500 East Medical Center Drive, Ann Arbor, MI 48109en_US
dc.identifier.pmid21656753en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/87175/1/25862_ftp.pdf
dc.identifier.doi10.1002/cncr.25862en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceAmerican Cancer Society. Breast Cancer Facts & Figures, 2009‐2010. Atlanta, GA: American Cancer Society; 2010.en_US
dc.identifier.citedreferenceBerry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784 ‐ 1792.en_US
dc.identifier.citedreferenceAnderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002; 76: 27 ‐ 36.en_US
dc.identifier.citedreferenceUS Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 151: 716 ‐ 726, W‐236.en_US
dc.identifier.citedreferenceParise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol. 2010; 76: 44 ‐ 52.en_US
dc.identifier.citedreferenceParise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999‐2004. Breast J. 2009; 15: 593 ‐ 602.en_US
dc.identifier.citedreferenceBrown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: the California Cancer Registry, 1999‐2004. Cancer. 2008; 112: 737 ‐ 747.en_US
dc.identifier.citedreferenceBauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype: a population‐based study from the California Cancer Registry. Cancer. 2007; 109: 1721 ‐ 1728.en_US
dc.identifier.citedreferenceNational Cancer Institute; Surveillance, Epidemiology and End Results Program. SEER*Stat software, version 6.5.2. http://seer.cancer.gov/seerstat/. Accessed December 1, 2009.en_US
dc.identifier.citedreferenceRomond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2‐positive breast cancer. N Engl J Med. 2005; 353: 1673 ‐ 1684.en_US
dc.identifier.citedreferencePiccart‐Gebhart MJ, Procter M, Leyland‐Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2‐positive breast cancer. N Engl J Med. 2005; 353: 1659 ‐ 1672.en_US
dc.identifier.citedreferenceHorner MJ, Ries LAG, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975‐2006 [based on the November 2008 SEER data submission, posted to the SEER website, 2009]. Bethesda, MD: National Cancer Institute; 2009.en_US
dc.identifier.citedreferenceMorris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African‐American and Caucasian patients: a single‐institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110: 876 ‐ 884.en_US
dc.identifier.citedreferenceLund MJ, Butler EN, Bumpers HL, et al. High prevalence of triple‐negative tumors in an urban cancer center. Cancer. 2008; 113: 608 ‐ 615.en_US
dc.identifier.citedreferenceLund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population‐based study in Atlanta, GA. Breast Cancer Res Treat. 2009; 113: 357 ‐ 370.en_US
dc.identifier.citedreferenceMoran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG. Long‐term outcomes and clinicopathologic differences of African‐American versus white patients treated with breast conservation therapy for early stage breast cancer. Cancer. 2008; 113: 2565 ‐ 2574.en_US
dc.identifier.citedreferenceCarey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492 ‐ 2502.en_US
dc.identifier.citedreferenceNelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the US Preventive Services Task Force. Ann Intern Med. 2009; 151: 727 ‐ 737, W237‐W242.en_US
dc.identifier.citedreferenceMandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009; 151: 738 ‐ 747.en_US
dc.identifier.citedreferenceYang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor‐negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008; 111: 405 ‐ 410.en_US
dc.identifier.citedreferenceYang TJ, Yang Q, Haffty BG, Moran MS. Prognosis for mammographically occult, early stage breast cancer patients treated with breast‐conservation therapy. Int J Radiat Oncol Biol Phys. 2010; 76: 79 ‐ 84.en_US
dc.identifier.citedreferenceKojima Y, Tsunoda H. Mammography and ultrasound features of triple‐negative breast cancer [published online ahead of print October 23, 2010]. Breast Cancer. 2010.en_US
dc.identifier.citedreferenceKo ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA. Triple‐negative breast cancer: correlation between imaging and pathological findings. Eur Radiol. 2010; 20: 1111 ‐ 1117.en_US
dc.identifier.citedreferenceMa H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G. Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple‐negative breast cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 479 ‐ 485.en_US
dc.identifier.citedreferenceMillikan RC, Newman B, Tse CK, et al. Epidemiology of basal‐like breast cancer. Breast Cancer Res Treat. 2008; 109: 123 ‐ 139.en_US
dc.identifier.citedreferencePalmer JR, Wise LA, Horton NJ, Adams‐Campbell LL, Rosenberg L. Dual effect of parity on breast cancer risk in African‐American women. J Natl Cancer Inst. 2003; 95: 478 ‐ 483.en_US
dc.identifier.citedreferenceUrsin G, Bernstein L, Wang Y, et al. Reproductive factors and risk of breast carcinoma in a study of white and African‐American women. Cancer. 2004; 101: 353 ‐ 362.en_US
dc.identifier.citedreferenceHuo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over‐representation of triple‐negative breast cancer. J Clin Oncol. 2009; 27: 4515 ‐ 4521.en_US
dc.identifier.citedreferenceBird PA, Hill AG, Houssami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol. 2008; 15: 1983 ‐ 1988.en_US
dc.identifier.citedreferenceStark A, Kleer CG, Martin I, et al. African ancestry and higher prevalence of triple‐negative breast cancer: findings from an international study. Cancer. 2010; 116: 4926 ‐ 4932.en_US
dc.identifier.citedreferenceFregene A, Newman LA. Breast cancer in sub‐Saharan Africa: how does it relate to breast cancer in African‐American women? Cancer. 2005; 103: 1540 ‐ 1550.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.